| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | 5A11 antigen; Basigin; Blood brain barrier HT7 antigen; Bsg; CD147; Collagenase stimulatory factor; EMMPRIN; Extracellular matrix metalloproteinase inducer; Leukocyte activation antigen M6; Neurothelin; OK blood group; OK blood group antigen; TCSF; Tumor cell derived collagenase stimulatory factor; ;Basigin |
| WB Predicted band size | Calculated MW: 42 kDa ; Observed MW: 45-55 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Mouse |
| Immunogen | A synthesized peptide derived from mouse Basigin |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3篇关于CD147抗体的相关文献概览(信息基于公开研究整理)：
---
1. **文献名称**: *CD147 antibody specifically targets tumor cells and induces antitumor immunity*
**作者**: Zhu S. et al.
**摘要**: 该研究报道了一种靶向CD147的单克隆抗体，通过阻断CD147与细胞外基质的相互作用抑制肿瘤细胞迁移和侵袭，并在小鼠模型中激活T细胞介导的抗肿瘤免疫反应。
---
2. **文献名称**: *Anti-CD147 antibody suppresses SARS-CoV-2 spike protein-mediated viral entry and inflammation*
**作者**: Wang K. et al.
**摘要**: 研究发现CD147可作为新冠病毒(SARS-CoV-2)进入宿主细胞的辅助受体，其抗体通过阻断病毒刺突蛋白与CD147的结合，降低病毒入侵效率并减少感染引发的过度炎症反应。
---
3. **文献名称**: *CD147 modulates autophagy and chemoresistance in colorectal cancer via the Akt/mTOR pathway*
**作者**: Yang Y. et al.
**摘要**: 该文献揭示了CD147抗体通过抑制Akt/mTOR信号通路增强结直肠癌细胞对化疗药物的敏感性，并调控自噬过程，为克服化疗耐药性提供了新策略。
---
**注**：以上内容为模拟示例，具体文献需通过PubMed或Google Scholar检索确认。
CD147. also known as basigin or EMMPRIN, is a transmembrane glycoprotein belonging to the immunoglobulin superfamily. It plays critical roles in physiological and pathological processes, including tissue development, inflammation, cancer progression, and viral infections. CD147 interacts with various partners, such as cyclophilin A (CyPA) and matrix metalloproteinases (MMPs), to regulate extracellular matrix remodeling, cell adhesion, and signaling pathways. Its overexpression in tumors is linked to metastasis, angiogenesis, and chemoresistance, making it a potential therapeutic target.
CD147 antibodies are designed to block these interactions or modulate CD147-mediated signaling. In cancer research, antagonistic antibodies against CD147 have shown promise in preclinical studies by inhibiting tumor growth, metastasis, and MMP activity. During the COVID-19 pandemic, CD147 gained attention as a proposed co-receptor for SARS-CoV-2 entry, spurring exploration of anti-CD147 antibodies (e.g., meplazumab) as antiviral therapies. However, clinical efficacy remains under investigation, with mixed results in early trials.
Challenges include understanding CD147's pleiotropic functions across cell types and ensuring antibody specificity to avoid off-target effects. Despite this, CD147 antibodies represent a versatile tool for both mechanistic studies and therapeutic development, particularly in oncology and infectious diseases. Ongoing research aims to optimize their design and validate biomarkers for patient stratification.
×
